Novavax

YTD

ALL

Trade Novavax 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NVAX

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines.

CEO

John C.s Jacobs

CEOJohn C.s Jacobs

Employees

749

Employees749

Headquarters

Gaithersburg, Maryland

HeadquartersGaithersburg, Maryland

Founded

1987

Founded1987

Employees

749

Employees749

NVAX Key Statistics

Market cap

1.71B

Market cap1.71B

Price-Earnings ratio

-6.78

Price-Earnings ratio-6.78

Dividend yield

—

Dividend yield—

Average volume

6.24M

Average volume6.24M

High today

$10.48

High today$10.48

Low today

$9.90

Low today$9.90

Open price

$10.44

Open price$10.44

Volume

6.21M

Volume6.21M

52 Week high

$11.97

52 Week high$11.97

52 Week low

$6.20

52 Week low$6.20

Stock Snapshot

With a market cap of 1.71B, Novavax(NVAX) trades at $10.29. The stock has a price-to-earnings ratio of -6.78.

On 2026-09-03, Novavax(NVAX) stock moved within a range of $9.90 to $10.48. With shares now at $10.29, the stock is trading +3.9% above its intraday low and -1.9% below the session's peak.

Trading activity shows a volume of 6.21M, compared to an average daily volume of 6.24M.

Over the past 52 weeks, Novavax(NVAX) stock has traded between a high of $11.97 and a low of $6.20.

NVAX News

Benzinga 1d

Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor

Novavax Inc. (NASDAQ:NVAX) shares are trading higher. Strength may be due to an increase in investor attention related to an unconfirmed rumor suggesting that M...

Simply Wall St 2d

Novavax Could Be 34% Overvalued Following XFG Vaccine Approvals

Novavax (NVAX) is back in focus after announcing that partners secured approvals for an updated Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for t...

24/7 Wall St. 2d

Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?

Investing Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story? Retail traders are piling into Novavax on cancer-vaccine specu...

Analyst ratings

57%

of 7 ratings

Buy

57.1%

Hold

14.3%

Sell

28.6%

More NVAX News

Benzinga 2d

What's Going On With Novavax Stock?

Shares of Novavax Inc (NASDAQ:NVAX) are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authori...

Benzinga 3d

Novavax Stock Climbs Monday: What's Going On?

Shares of Novavax Inc. (NASDAQ:NVAX) are trading higher Monday morning. The stock is extending its 30% monthly gains as investors respond positively to regulato...

TipRanks 6d

Novavax’s partners approved for Nuvaxovid formulation for vaccination season

Novavax’s (NVAX) partners have received approvals for the Nuvaxovid formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in maj...

People also own

Based on the portfolios of people who own NVAX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.